Transplant Immunosuppressive Drugs Market Size, Share, Opportunities, COVID-19 Impact, And Trends By Type (Induction Drugs, Maintenance Drugs), By Application (Tissue Transplantation, Organ Transplantation), And By Geography – Forecast From 2022 To 2027

Published:  Mar 2022 Report Code: KSI061612968 Pages: 121

Transplant Immunosuppressive Drugs Market is expected to grow at a compound annual growth rate of 3.32% over the forecast period to reach a market size of US$10.336 billion in 2027 from US$8.224 billion in 2020.


Transplant immunosuppressive drugs are used by patients who have had organ transplant surgery in the past.  These drugs are helpful in protecting patients against rejection of the transplanted foreign organ by their own bodies. Moreover, the rising prevalence of chronic diseases such as cardiovascular disease, diabetes, cancer, and asthma are expected to increase the demand for organ transplants, which will further boost the transplant immunosuppressive drugs market during the forecast period. Technological advancements made by biotechnology and medical device companies in novel transplant products, an increasing number of tissue banks, and rising healthcare expenditure across various countries are anticipated to drive the overall growth of the market. Based on the report published by the United Network for Organ Sharing (UNOS) on organ transplantation, it was estimated that the total number of transplants that were performed in 2018 was around 26,448. This included kidney (21,167), liver (8,250), heart (3,408), lung (2,530), kidney and pancreas (836), pancreas (192), intestine (104), heart/lung (32), and vascular allograft (11) transplant procedures.

Market Drivers

  • Rising organ transplant surgeries

One of the primary reasons driving the market's growth is the increased organ transplant surgeries. According to the health resources and services administration, 39,000 transplants were performed in 2020, and 106,795 men, women, and children are on the waiting list for organ transplants in the United States. Moreover, the rising incidence of vital organ failure and increasing awareness about organ procurement and transplantation are anticipated to drive the transplant immunosuppressive drug market during the forecast period. According to the data published by  Transplant Australia, the Australian organ donation rate is currently 18.0 donors per million. In 2020, 463 deceased organ donors and 182 living donors gave 1,452 Australians a new chance in life. The most common transplanted organs are the kidney, liver, heart, lungs, and pancreas. Furthermore, the increasing incidence of chronic diseases is expected to increase the demand for organ transplant procedures, which will further drive the overall market growth. Advancement in tissue engineering and organ transplantation is expected to positively increase the market growth. Tissue engineering helps in replacing failed organs with the help of tailored organs. It helps in creating a functional artificially produced organ. According to the U.S. government’s organ donation and transplantation report, more than 100,000 patients are on the 2019 waiting list for organ transplantation, and the main problem that is arising is the shortage of organ donations.

Competitive Insights

The increasing demand for organ transplants has led to the entry of several new players in the transplant immunosuppressive drug market. To increase their clientele as well as increase their market share in the upcoming years, many of these market players have taken various strategic actions like partnerships and the development of novel solutions, which are expected to keep the market competitive and constantly evolving. Major market players like Astellas Pharma Inc. and Novartis Pharmaceuticals Corporation, among others, have been covered along with their relative competitive strategies. The report also mentions recent deals and investments by different market players over the last few years. The company profiles section details the business overview, financial performance (public companies) for the past few years, key products and services being offered, along with the recent deals and investments of these important players in the transplant immunosuppressive drugs market.

Transplant Immunosuppressive Drugs Market Scope:

Report Metric Details
 Market size value in 2020  US$8.224 billion
 Market size value in 2027  US$10.336 billion
 Growth Rate  CAGR of 3.32% from 2020 to 2027
 Base year  2020
 Forecast period  2022–2027
 Forecast Unit (Value)  USD Billion
 Segments covered  Type, Application, And Geography
 Regions covered  North America, South America, Europe, Middle East and Africa, Asia Pacific
 Companies covered Astellas Pharma Inc., Bristol-Myers Squibb Company, Sanofi Genzyme, Novartis Pharmaceuticals Corporation, Mylan N.V., F. Hoffmann-La Roche Ltd.
 Customization scope  Free report customization with purchase



  • By Type
    • Induction Drugs
    • Maintenance Drugs
  • By Application
    • Tissue Transplantation
    • Organ Transplantation
  • By Geography
    • North America
      • USA
      • Canada
      • Mexico
    • South America
      • Brazil
      • Argentina
      • Others
    • Europe
      • Germany
      • France
      • United Kingdom
      • Spain
      • Others
    • Middle East and Africa
      • Saudi Arabia
      • Israel
      • Others
    • Asia Pacific
      • China
      • Japan
      • South Korea
      • India
      • Others

1. Introduction
1.1. Market Definition
1.2. Market Segmentation

2. Research Methodology
2.1. Research Data
2.2. Assumptions

3. Executive Summary
3.1. Research Highlights

4. Market Dynamics
4.1. Market Drivers
4.2. Market Restraints
4.3. Porters Five Forces Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Power of Buyers
4.3.3. The threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Function
4.4. Function Value Chain Analysis

5.1. Induction Drugs
5.2. Maintenance Drugs

6.1. Tissue Transplantation
6.2. Organ Transplantation

7.1. North America
7.1.1. USA
7.1.2. Canada
7.1.3. Mexico
7.2. South America
7.2.1. Brazil
7.2.2. Argentina
7.2.3. Others
7.3. Europe
7.3.1. United Kingdom
7.3.2. Germany
7.3.3. France
7.3.4. Others
7.4. Middle East and Africa
7.4.1. Saudi Arabia
7.4.2. UAE
7.4.3. Others
7.5. Asia Pacific
7.5.1. China
7.5.2. Japan
7.5.3. India
7.5.4. South Korea
7.5.5 Others

8.1. Competitive Benchmarking and Analysis
8.2. Recent Investments and Deals
8.3. Strategies of Key Players

9.1 Astellas Pharma Inc.
9.2 Bristol-Myers Squibb Company
9.3 Sanofi Genzyme
9.4 Novartis Pharmaceuticals Corporation
9.5 Mylan N.V.
9.6 F. Hoffmann-La Roche Ltd.

Astellas Pharma Inc.

Bristol-Myers Squibb Company

Sanofi Genzyme

Novartis Pharmaceuticals Corporation

Mylan N.V.

Hoffmann-La Roche Ltd.



Explore Custom Options available with this study:

  •  Request customization
  •  Buy sections of the study
  •  Buy country specific report
  •  Request excel, Historical data
  •  Subscription inquiry
  •  Request special pricing

Our Value Proposition

Analyst Support

All our studies come with 2 months of analyst support.


We are in compliance with the global privacy laws.

Connect With Us